Alector, Inc. (ALEC) is a South San Francisco clinical-stage biotechnology company developing antibody, enzyme, and siRNA therapies for neurodegenerative disease, built around its proprietary Alector Brain Carrier platform for shuttling drugs across the blood-brain barrier. Shares changed hands at $2.36 at midday Thursday, down $0.21, or 8.17%, from the prior close of $2.57. The direction is unambiguously negative. No verified news catalyst was found for the drop; the decline fits a pattern of profit-taking after a sharp six-week advance and a rejection at the stock's 52-week high.
No verified news or fundamental catalyst found explains Thursday's decline. Alector has not published a press release, filed an 8-K, or disclosed trial or regulatory news this week, and no analyst rating or target change was issued ahead of the move. The most recent company-specific items were its third-quarter report on Nov. 5 and a $7 price objective from Wells Fargo on Nov. 13, both of which preceded the rally that peaked two sessions later.
The likely cause is technical and positioning-driven. Alector climbed from $1.81 on Oct. 2 to an intraday $2.84 on Nov. 11 — a 57% peak gain in 28 sessions — then failed to hold that level and began drifting lower. Thursday's action accelerated that retracement, with the stock breaking below its 10-day moving average near $2.47 but remaining above its 20-day average around $2.27. Short interest of roughly 8.4 million shares, about 3.6 days of trading volume, likely amplified the slide as momentum buyers exited. Thin liquidity in a sub-$400 million market capitalization name can turn a modest wave of sell orders into an outsized percentage move, and this is consistent with a routine retracement rather than a reassessment of the business.
The broader environment was supportive, which makes Alector's decline idiosyncratic. Biotech benchmarks were higher, with XBI and IBB both in positive territory, and clinical-stage peers joined the advance: SRRK gained 4.79%, PRAX added 2.17%, and BEAM rose 1.86%. With the sector in the green, Alector's underperformance reflects stock-specific supply rather than a risk-off rotation. Attention in the space remains fixed on two FDA decisions scheduled for Nov. 22 involving Capricor and Savara, plus Alzheimer's data presentations this week — events that carry read-through for sentiment toward neurodegeneration names but not for Alector's own pipeline.
Turnover is running near a normal pace rather than showing the surge that typically accompanies news-driven selling, with roughly half a million shares changing hands by midday against a recent daily average of about 1.1 million. That profile supports a supply-and-demand explanation rather than an information shock. The stock traded as low as roughly $2.31, about 10% below the prior close, before stabilizing. It remains far above its 52-week low of $1.09 but has surrendered a meaningful slice of its autumn gains. The failure at $2.84 — the top of the range — and the loss of the 10-day average are the two technical markers that mattered most.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Alector's score is 13 out of 100.
The verified news component is essentially absent, contributing almost nothing, since nothing material was disclosed and the most recent corporate events were already public before the rally began. The price component is also low: an 8.17% decline is only about 1.8 times the stock's typical absolute daily move of roughly 4.5%, and moves of this size or larger occurred 11 times in the past 88 sessions. With both components weak, the combination produces a low score.
Alector's next scheduled financial update is its fourth-quarter and full-year report, expected in the first quarter of 2027. The company ended the third quarter with a cash runway projected into the second half of 2029, supported by the $100 million upfront payment from Genentech for AL050 and roughly $75 million in net proceeds from an October equity offering — a cushion that removes near-term financing pressure but also reflects dilution.
The pipeline calendar is thin. First-in-human subcutaneous dosing of AL137 in Australia is targeted for April 2027, with a U.S. IND submission planned for the second quarter of 2027, while AL164 and AL062 are not expected to enter the clinic until 2028. With no active clinical trials generating readouts, the shares are likely to remain driven by sentiment, analyst revisions, and sector rotation. Key risks include the absence of near-term catalysts, execution risk on early-stage programs, and the possibility that consensus expectations drift lower during the quiet period. Analyst opinion remains split, with ratings spanning Buy to Underweight.
Tickeron maintains hundreds of AI trading bots that cover thousands of tickers across equities, ETFs, and other markets, but only the strongest performers under current market conditions are surfaced in the curated Trending AI Robots section. Bots differ widely in strategy, timeframe, performance metrics, and the symbols they trade, so the selection refreshes as market conditions shift. Reviewing this list can help investors see which automated approaches are currently keeping pace with volatile names like Alector.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The Moving Average Convergence Divergence (MACD) for ALEC turned positive on October 27, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALEC as a result. In 78 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
ALEC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 219 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The 10-day RSI Indicator for ALEC moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 64 cases where ALEC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ALEC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALEC entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.646) is normal, around the industry mean (3.592). P/E Ratio (-2.101) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders
Industry Biotechnology